English
Brain development is an extremely complex process that depends on genetically determined factors and on the electrical activity of the brain. These activities arise from the third trimester of pregnancy and play an important role in the construction of cortical maps. Many studies have shown that fundamental changes in patterns of brain activity could ultimately lead to neurological dysfunction. Nearly 50 % of children with intellectual disability have epilepsy, and one of the fundamental questions is to determine the role of epileptic seizures in the cognitive impairment. Our consortium is particularly interested by Early Onset Epileptic Encephalopathies (EOEE), a group of rare devastating epileptic syndromes of infancy imposing an enormous socio-economic burden on families and society. They are characterized by epileptic activity that consists of frequent seizures and/or major interictal paroxysmal activity accompanied by rapid deterioration of brain function with progressive disturbance of cognitive, sensory or motor functions. EOEE show a high degree of variability, both in terms of electro-clinical manifestations, contingent pathophysiological bases and etiologies. We have created a cohort of 208 EOEE patients (as 01/05/2014) for which all available medical information is collected. Patients with brain malformations or metabolic diseases, that are a known cause of EOEE, are excluded from the cohort. There is a strong genetic basis for EOEE and the cohort is thus genetically explored. We and other laboratories found that KCNQ2 (potassium channel, voltage-gated, KQT-like subfamily, member 2) is a major gene involved in EOEE. In our cohort, to date, de novo mutations of KCNQ2 were found in 18 patients (and 6 additional mutations for which parental origin could not be determined). These findings indicate that KCNQ2 mutations are a significant cause of EOEE. This is quite unexpected because KCNQ2 mutations are traditionally described in patients with a much milder form of childhood epilepsy called benign familial neonatal seizures (BFNS). In BFNS, seizures also start at birth and stop before the end of the third month, but in contrast to severe forms of KCNQ2-related epilepsies, interictal activity is normal, as well as the cognitive outcome of most children. The fact that mutations in the same gene can give rise either to benign seizures or to dramatic epileptic outbreaks followed by intellectual disability demonstrates the importance of KCNQ2 in brain development and suggests that the resulting potassium current may be differently affected in these 2 diseases. We propose to take advantage of the large number of mutations that we found in KCNQ2, combined with the extensive clinical information available in our cohort in order to understand the mechanisms by which KCNQ2 mutations cause epileptic encephalopathies and to set the foundation for improvement of the medical care of EOEE patients. We will use a combination of genetic, electrophysiological, biochemical and cellular analyses in vivo and in vitro in various models and cellular compartments to answer the following questions: 1- is the severity of seizures and their consequences on brain development related to the degree of potassium current inhibition and to the alterations of the level of neuronal excitability ? 2- is it possible to restore channel functionality in EOEE patients ? Beyond the clinical and translational aspects of our project, the results obtained will improve our knowledge on the regulation of KCNQ channel, their function during brain development and synaptic plasticity. Hopefully, this project will ultimately translate into a clinical trial for KCNQ2 related EOEE patients, an objective already reached for another neurological disease by one of the partners of this project.
